drugset
drugset / Trial / NCT00316550

Pilot Study to Assess the Effects of AV608 on Irritable Bowel Syndrome

NCT00316550 ↗

Phase 1 Terminated 24 enrolled Avera Pharmaceuticals University of California, Los Angeles · collab
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study is to assess the effects of AV608, a neurokinin 1 (NK-1) antagonist, in subjects with Irritable Bowel Syndrome.

Timeline

Start
2006-04
Primary completion
2007-06
Completion
2007-09

Outcome

Outcome not reported

Stopped: “Animal Safety Data”

Drugs

EvaluationDrugModalityDoseRoute
Subject AV608 Unknown — —

Indications

irritable bowel syndrome